Molina Healthcare says it will drop its traditional Medicare Advantage prescription drug plans starting with the 2027 plan year, walking away from a product line that brings in roughly $1 billion a year in premiums. The insurer disclosed the move inside its own fourth-quarter 2025 earnings report, framing it as a strategic pivot rather than a retreat from Medicare altogether. For the hundreds of thousands of people who count on Medicare Advantage for both medical care and drug coverage, a major carrier stepping back from one specific product type is worth understanding well before the actual exit date arrives.
The $1 Billion Product Molina Says No Longer Fits
Molina laid out the decision inside the same release where it reported full-year 2025 results and issued its 2026 guidance, published February 5, 2026. In that earnings release, the company stated it plainly: “The Company has determined the MAPD product with approximately $1 billion in annual premium does not align with its strategic shift to focus exclusively on its $5 billion dual eligible business in Medicare. The Company will exit the MAPD product for 2027.”
MAPD stands for Medicare Advantage Prescription Drug plan, the traditional bundled product that combines hospital coverage, doctor visits and a prescription drug benefit into one private plan sold to anyone enrolled in Medicare. It is the plan type most people picture when they picture Medicare Advantage. Molina is not leaving Medicare; the company is exiting this one product line while keeping its dual-eligible plans, which serve people who qualify for both Medicare and Medicaid at the same time.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost you real money. The free Retirement Shield newsletter keeps you ahead of the deadlines that matter. Sign up free.
Why Molina Is Betting on Dual-Eligible Members Instead
The math behind the decision is straightforward on paper. Molina’s traditional MAPD product carries about $1 billion in annual premium, while the dual-eligible Medicare business the company plans to build around instead runs about $5 billion, five times the size, according to the same release. Dual-eligible members qualify for both Medicare and Medicaid, and health plans that specialize in serving them are typically paid through a combination of both programs rather than competing purely on the open Medicare Advantage market.
Molina’s own 2026 guidance, issued in that February release, projects total Medicare segment membership across all of its Medicare products falling from 262,000 people at the end of 2025 to roughly 230,000 by the end of 2026. The company did not break that projection down product by product, so it should not be read as a MAPD-specific enrollment count, but it shows a business that expects its Medicare book to keep shrinking and consolidating around fewer, more specialized products even before the MAPD exit formally takes effect.
What Happens to Current Molina Medicare Advantage Members
Nothing changes for the current plan year. Molina’s traditional MAPD plans keep running through the end of 2026, and the exit applies to the 2027 plan year, which starts January 1, 2027. Molina has not announced how or when it will send formal non-renewal notices to individual members.
When a Medicare Advantage plan does end its contract with Medicare or isn’t renewed for the coming year, federal rules guarantee affected members a chance to switch without waiting for the next full enrollment season. According to Medicare’s own special enrollment period rules, someone whose Medicare Advantage plan’s contract with Medicare isn’t renewed can switch to another Medicare Advantage plan or a stand-alone drug plan any time between December 8 and the last day of February the following year, and will be moved into Original Medicare automatically if they don’t pick a new plan themselves.
The Cost Molina Has Already Booked
The decision is not just a talking point on an earnings call; Molina has already put a number on it in its own financial statements. The company recorded a $93 million impairment charge during the six months ended June 30, 2026, tied directly to writing down the value of the MAPD product’s remaining intangible assets, including contract rights, provider networks and trade name value, now that it plans to exit the line.
Molina also confirmed the exit is still on track in its second-quarter 2026 results, published July 22, 2026, more than five months after the original announcement. That release states its full-year 2026 guidance “includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.” In plain terms, Molina is still losing money on the product it is phasing out, and it said so again in its most recent quarterly report.
The Enrollment Window That Matters Before 2027
Anyone with a Medicare Advantage plan, whether or not it is a Molina plan, already has one guaranteed chance every year to compare options and switch. Medicare’s Open Enrollment period runs every October 15 through December 7, and any changes made during that window take effect January 1 of the following year. This year’s window, October 15 through December 7, 2026, is the one that sets up coverage for 2027, which makes it the practical first checkpoint for anyone currently in a Molina Medicare Advantage drug plan who wants to see what else is available before their current plan is phased out.
People in that position do not have to wait for a formal notice from Molina to start looking. Medicare’s plan-comparison tools are open to everyone year-round, and using the same October-to-December window that already governs every other Medicare Advantage decision means nobody enrolled in Molina’s soon-to-be-discontinued product has to make a rushed choice once 2027 arrives.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
